[go: up one dir, main page]

IL124442A0 - Methods of increasing lean tissue mass using ob protein compositions - Google Patents

Methods of increasing lean tissue mass using ob protein compositions

Info

Publication number
IL124442A0
IL124442A0 IL12444296A IL12444296A IL124442A0 IL 124442 A0 IL124442 A0 IL 124442A0 IL 12444296 A IL12444296 A IL 12444296A IL 12444296 A IL12444296 A IL 12444296A IL 124442 A0 IL124442 A0 IL 124442A0
Authority
IL
Israel
Prior art keywords
methods
protein compositions
tissue mass
lean tissue
increasing lean
Prior art date
Application number
IL12444296A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL124442A0 publication Critical patent/IL124442A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12444296A 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions IL124442A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
PCT/US1996/017718 WO1997018833A1 (fr) 1995-11-22 1996-11-04 Procedes permettant d'accroitre la masse tissulaire maigre a l'aide de compositions a base de proteine ob

Publications (1)

Publication Number Publication Date
IL124442A0 true IL124442A0 (en) 1998-12-06

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12444296A IL124442A0 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions
IL127926A IL127926A (en) 1995-11-22 1999-01-05 Fusion protein comprising all, or a portion, of an antibody constant portion, of an antibody constant region, attached to the n-terminus of a human ob protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL127926A IL127926A (en) 1995-11-22 1999-01-05 Fusion protein comprising all, or a portion, of an antibody constant portion, of an antibody constant region, attached to the n-terminus of a human ob protein

Country Status (15)

Country Link
EP (3) EP0956862A1 (fr)
JP (2) JP4173914B2 (fr)
AT (2) ATE259243T1 (fr)
AU (3) AU7607496A (fr)
CA (2) CA2358862A1 (fr)
DE (2) DE69631544T2 (fr)
DK (1) DK0866720T3 (fr)
ES (2) ES2217327T3 (fr)
IL (2) IL124442A0 (fr)
MX (1) MX9803992A (fr)
NZ (3) NZ527007A (fr)
PT (1) PT866720E (fr)
SI (1) SI0866720T1 (fr)
WO (1) WO1997018833A1 (fr)
ZA (1) ZA969605B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
CA2274799A1 (fr) * 1996-12-20 1998-07-02 Eli Lilly And Company Proteines anti-obesite
KR100937550B1 (ko) * 1996-12-20 2010-01-19 암젠 인코포레이티드 Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (fr) * 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
AU781460B2 (en) * 1999-02-12 2005-05-26 Amgen, Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CA2464277C (fr) 2001-10-22 2013-02-05 Amgen, Inc. Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
EP1496838B1 (fr) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Amides substitues
WO2006005058A2 (fr) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
EP1814590B2 (fr) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Traitement contre l'obesite ainsi que les maladies associees a l'obesite
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2008048691A2 (fr) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Utilisation de leptine pour le traitement de dépôt de graisse ectopique après une lipectomie et d'autres troubles associés après une lipectomie
WO2009149379A2 (fr) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Utilisation de leptine pour le traitement de maladies et affections de stéatose hépatique
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
JP6480864B2 (ja) 2012-09-27 2019-03-13 ザ チルドレンズ メディカル センター コーポレーション 肥満の処置のための化合物およびそれの使用方法
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
WO2015153933A1 (fr) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Inhibiteurs hsp 90 pour le traitement de l'obésité et leurs procédés d'utilisation
ES2959990T3 (es) 2016-09-12 2024-02-29 Amryt Pharmaceuticals Inc Métodos de detección de anticuerpos neutralizantes dirigidos contra la leptina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
DE59405967D1 (de) * 1993-08-13 1998-06-18 Putzmeister Ag Verfahren und anordnung zur oberflächenbearbeitung von grossobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
KR100937550B1 (ko) * 1996-12-20 2010-01-19 암젠 인코포레이티드 Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법
JP4086908B2 (ja) * 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法

Also Published As

Publication number Publication date
DE69631544T2 (de) 2004-12-23
CA2358862A1 (fr) 1997-05-29
DE69631544D1 (de) 2004-03-18
EP1285664A3 (fr) 2003-07-30
JP2002206000A (ja) 2002-07-23
ES2339846T3 (es) 2010-05-26
EP0866720A1 (fr) 1998-09-30
EP1285664B1 (fr) 2010-01-20
JP2000500492A (ja) 2000-01-18
CA2236163A1 (fr) 1997-05-29
AU4265300A (en) 2000-09-07
AU763769B2 (en) 2003-07-31
AU4265200A (en) 2000-09-21
IL127926A0 (en) 1999-11-30
JP4227325B2 (ja) 2009-02-18
PT866720E (pt) 2004-06-30
IL127926A (en) 2006-08-20
EP0866720B1 (fr) 2004-02-11
JP4173914B2 (ja) 2008-10-29
NZ527007A (en) 2005-01-28
AU763755B2 (en) 2003-07-31
DE69638119D1 (de) 2010-03-11
AU7607496A (en) 1997-06-11
ZA969605B (en) 1997-06-02
ATE259243T1 (de) 2004-02-15
WO1997018833A1 (fr) 1997-05-29
ATE455554T1 (de) 2010-02-15
DK0866720T3 (da) 2004-06-14
ES2217327T3 (es) 2004-11-01
EP0956862A1 (fr) 1999-11-17
SI0866720T1 (en) 2004-10-31
MX9803992A (es) 1998-09-30
EP1285664A2 (fr) 2003-02-26
NZ511617A (en) 2003-08-29
NZ512083A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
IL124442A0 (en) Methods of increasing lean tissue mass using ob protein compositions
IL189629A0 (en) Compositions containing human ctla-4 antibodies
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MXPA05004225A (es) Anticuerpos de neutralizacion contra gdf-8, y sus usos.
AU4230493A (en) Diphtheria toxin receptor-binding region
AU4399297A (en) Reconstituted human anti-hm1.24 antibody
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
ES2191298T3 (es) Cuerpo de implantes.
ZA976181B (en) Methods of enhancing lean tissue mass and bone mineral content and compositions therefor.
DE69830143D1 (en) Phosphodiesterase 8
WO1997020933A3 (fr) VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
EP0816504A3 (fr) Facteur d'activation des plaquettes acétylhydrolase, et gène codant celui-ci
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
HUP0102577A3 (en) Seeding crystals for the preparation of peptides or proteins, process for their preparation and their use
AUPN674895A0 (en) Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
AU5569600A (en) Novel protein and dna thereof
AU6860294A (en) New chondrocyte proteins
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU6223599A (en) Artificial ligament or biological tissue fixation devices
AU3703795A (en) Chondrocyte cell-lines
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
WO1999046381A3 (fr) Gene du fgf humain et produit d'expression genique
AU8499501A (en) Slo2 and slo4, novel potassium channel proteins from human brain
AU2003201360A1 (en) Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees